DSHS Announces Distribution of Remdesivir to Hospitals

News Release
News Release
May 12, 2020

News Release
May 12, 2020

The Texas Department of StateHealth Services is distributing 1,200 vials of the drug remdesivir to hospitalsto treat patients with COVID-19. The antiviral medication, which has shownpromise in early trials in speeding up the recovery time among hospitalized COVID-19patients, has been provided by the federal government from a supply donated byGilead, the manufacturer.

The U.S. Department of Health andHuman Services sent Texas 30 cases of remdesivir, enough to treat approximately120 patients. Each case contains 40 vials of the drug. DSHS consulted on the distributionrationale with the Texas Hospital Association, Texas Medical Association, andthe Rapid Assessment Subcommittee of the Texas Task Force on Infectious DiseasePreparedness and Response.

Texas is shipping the limitedsupply today to 15 hospitals in 14 communities, ensuring that patients inregions across the state will have access to the drug while providingadditional supplies to areas that have had more COVID-19 cases. Additionally,some hospitals in Texas are able to receive remdesivir through clinical trialsor the manufacturer’s expanded access program. Where that’s the case, the statesupply is being directed to other facilities in the area.

The following hospitals and healthcare systems will receive at least one case of remdesivir:

  • Amarillo:Northwest Texas Healthcare System, 2 cases
  • Austin:Dell Seton Medical Center, 3 cases
  • CorpusChristi: CHRISTUS Spohn Health System, 1 case
  • Dallas:Parkland Memorial Hospital, 4 cases
  • ElPaso: University Medical Center, 2 cases
  • FortWorth: John Peter Smith Hospital, 3 cases
  • Houston:Ben Taub Hospital & Memorial Hermann Hospital System, 6 cases
  • Laredo:Laredo Medical Center, 1 case
  • Lubbock:University Medical Center, 1 case
  • McAllen:South Texas Health System, 1 case
  • Odessa:Medical Center Hospital, 1 case
  • SanAntonio: University Hospital System, 3 cases
  • Tyler:Mother Frances Hospital, 1 case
  • Waco:Providence Health Center, 1 case

Medical staff at each hospital willdetermine how the drug will be used, though it must be prescribed in accordancewith the Food and Drug Administration’s EmergencyUse Authorization,allowing for the treatment of suspected or confirmed COVID-19 in adults andchildren hospitalized with severe disease. Preliminary results from a clinicaltrial showed the average recovery time among patients who received remdesivir was11 days versus 15 days with a placebo. Those preliminary results did not showsignificant survival benefit.

-30-   

DSHS Press Office on Twitter